Automating clinical-grade allogeneic cell therapy manufacturing: NorthX and Mendus case study in tech transfer, efficiency, and scale-out

This webinar looks at allogeneic cell therapy manufacturing through a single transfer. NorthX Biologics and Mendus moved an allogeneic dendritic cell immune therapy into clinical-grade, automated production. The speakers show how early process design shapes transfer success, product consistency and the route to commercial supply.

The session also covers hollow-fiber perfusion technology and where automation fits across CAR-T, TCR-T, MSC and iPSC workflows. Ola Tuvesson, Chief Technology Officer at NorthX Biologics, presents with Maria Knaub of Terumo Blood and Cell Technologies. Terumo sponsors the webinar.

Process development, manufacturing and CMC roles will get the most from it. The webinar runs on 12 November 2026 at 17:00 CET, participation requires registration.